GlassScriptPhysician profile
Jerry Aprn Kunkel
NPI 1548781164
$12,778.12
in general payments reported to CMS, 2019-2025
24 companies · $5,794 in 2025
The $5,794 reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $353 · 2022: $652 · 2023: $1,449 · 2024: $4,530 · 2025: $5,794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,100 · Food and Beverage: $5,463 · Travel and Lodging: $202 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,100.00 |
| Food and Beverage | $5,462.64 |
| Travel and Lodging | $201.64 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $7,520.90 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,188.28 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $862.60 | 2022-2025 | Rexulti, Nuedexta |
| Vanda Pharmaceuticals INC. | $566.37 | 2024-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $561.48 | 2022-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $343.97 | 2023-2025 | Auvelity |
| Lundbeck LLC | $324.11 | 2021-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $231.18 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Novo Nordisk INC | $186.91 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Ironshore Pharmaceuticals INC. | $168.67 | 2022-2024 | Jornay Pm |
| Lilly USA, LLC | $149.22 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Supernus Pharmaceuticals, INC. | $135.29 | 2021-2025 | Qelbree |
| Alkermes, INC. | $130.03 | 2022-2024 | Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $108.10 | 2021-2025 | Spravato |
| Avanir Pharmaceuticals, INC. | $66.30 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $39.09 | 2021-2022 | |
| Almatica Pharma LLC | $37.54 | 2024-2025 | Loreev Xr |
| Medtronic, INC. | $33.53 | 2025 | Endurant Iis |
| Idorsia Pharmaceuticals US INC | $27.56 | 2023-2025 | Quviviq, Quviviq |
| Biogen, INC. | $26.56 | 2025 | Zurzuvae |
| Collegium Pharmaceutical, INC. | $24.84 | 2025 | Jornay Pm |
| Corcept Therapeutics | $15.81 | 2024 | Korlym |
| Merck Sharp & Dohme LLC | $15.03 | 2024 | Vaxneuvance, Gardasil 9, Gardasil |
| Glaxosmithkline, LLC. | $14.75 | 2023 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Kunkel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.